Between 2016 and 2019, the United States experienced a rapid proliferation of limits restricting the duration or number of doses in opioid prescriptions for acute pain.1 As of October 2019, such limits have been enacted by 34 states; large payers, such as Medicare, several state Medicaid programs, Aetna, and UnitedHealth; pharmacy chains, such as Sam’s Club/Walmart; and major pharmacy benefit managers, such as CVS CareMark, ExpressScripts, and OptumRx, which collectively manage drug benefits for 180 million Americans.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Chua K, Kimmel L, Brummett CM. Disappointing Early Results From Opioid Prescribing Limits for Acute Pain. JAMA Surg. 2020;155(5):375–376. doi:10.1001/jamasurg.2019.5891
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: